INNOPHARMAX develops oral new dosage form new drugs for further clinical development and commercialization, utilizing core drug delivery technology platforms OralPAS®, OralPAS Pro®, and MUCR. We are committed to improve the safety and efficacy of currently available drugs, and provide superior and cost effective medical options.
Looking for a particular Innopharmax employee's phone or email?
Innopharmax Questions
The Innopharmax annual revenue was $1 million in 2026.
Jason Hsu is the Director Of Business Development of Innopharmax.
15 people are employed at Innopharmax.
Innopharmax is based in Taipei, Taipei.
The NAICS codes for Innopharmax are [3254, 325, 32, 32541].
The SIC codes for Innopharmax are [28, 283].
Top Innopharmax Employees
-
Jason Hsu
Director Of Business Development at Innopharmax
New Taipei City, Taiwan1 -
煒堯 陳
Associate Director of R and D Department at Innopharmax
Taichung, Taichung City, TW1 -
Rung Fu
Research associate at Innopharmax
United Kingdom -
1
Related Companies
